Sexual consent and chemsex: a quantitative study on sexualised drug use and non-consensual sex among men who have sex with men in Amsterdam, the Netherlands

Susanne Drückler, Jilke Speulman, Martijn van Rooijen, Henry J C De Vries

ABSTRACT

Background Chemsex (drug use to enhance sex) has emerged among men who have sex with men (MSM). Non-consensual sex (NCS) is hypothesised to occur frequently under the influence of chemsex, however data are scarce. In this cross-sectional study, it was aimed to assess whether NCS is associated with chemsex.

Methods We offered a survey about chemsex in the past 6 months (crystal methamphetamine, mephedrone and/or gamma-hydroxybutyrate/gamma-butyrolactone use) and NCS (sexual experiences beyond one’s limits or unpleasant sexual experiences) in the past 5 years to Amsterdam-located gay dating platform users. Associations were assessed using \( \chi^2 \) test, Fisher’s exact test and multivariable logistic regression.

Results Of 891 participants, 30.6% (273 of 891) engaged in chemsex; 21.2% engaging and 16.7% not engaging in chemsex reported any NCS experiences (p=0.109). Among MSM who reported any NCS experiences, chemsex engagers reported being touched against one’s will less often compared with non-engagers (22.4% vs 39.8%; p=0.036). Yet, chemsex engagers reported passing out and not remembering what happened during drug use more often (41.4% vs 8.7%; p<0.001). The level of suffering from NCS experiences did not differ between chemsex engagers and non-engagers (p=0.539); and was rated by most participants with no suffering at all or low suffering (77.1%). In the multivariable regression analyses, chemsex engagement in the past 6 months was associated with NCS (adjusted OR 1.46; 95% CI 1.01 to 2.11).

Conclusions A substantial proportion of MSM (regardless of chemsex engagement) reported NCS in the past 5 years. In multivariate logistic regression analysis, chemsex engagement was associated with an NCS experience. Among participants who reported NCS, suffering related to NCS however, did not differ between chemsex engagers and non-engagers.

INTRODUCTION

Over the last decade, chemsex has become a rising phenomenon in the gay community. While there are different definitions of chemsex, here we define it as the use of any combination of the following drugs: crystal methamphetamine, mephedrone, and/or gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL) before or during sex by men who have sex with men (MSM). Chemsex can also include different or more drugs depending on the social context or geographical region. The majority of MSM engaging in chemsex do not self-identify with problematic drug use and hardly report any disadvantages in everyday life. Yet, some report a negative impact on their life and pressure from friends to engage in chemsex. Moreover, chemsex engagement is associated with sexual risk-taking behaviour such as condomless anal sex, and may possibly lead to negative physical and mental health consequences and addiction.

The meaning of chemsex engagement does not take into account the subculture and multifactorial issues surrounding the phenomenon of chemsex; for example, gay online dating culture and the fine line between consensual and non-consensual sex (NCS) are tightly linked to chemsex engagement and have become a more discussed topic in recent years. Chemsex engagement often takes place at home during sexualised parties with a small number of men who have met through dating applications or websites. A qualitative study reported that giving a notion of consent in a chemsex environment (characterised by sexually thrilling and loss of sexual desire control) felt difficult for some men.

There are many variations in terms for NCS, such as sexual harassment, molestation and forced sex; here we use the term NCS to address all sexual experiences beyond one’s limits or unpleasant sexual experiences. In the Netherlands, approximately 3.8% of men, regardless of sexuality, experienced oral/anal penetration without consent at least once in their life. Moreover, the prevalence of NCS is higher among gay and bisexual men, compared with heterosexual men.

Sexual consent is a human right, yet when drugs are involved it oftentimes becomes more difficult to consent and sexually transgressive behaviour seems to occur more easily. NCS among MSM—and especially during chemsex engagement—has been underexamined in research. Moreover, most research concerning
chemsex has (sexual) health outcomes as main focus. Therefore, here we aimed to study chemsex engagement in relation to NCS. So we assessed whether NCS is associated with chemsex engagement.

**METHOD**

**Data collection and study population**

Users of two online gay dating platforms (Grindr and Gayromeo) were invited to participate in an anonymous online survey through interstitial advertisement. The survey was online on both platforms until the paid budget was depleted and was only shown to users in the Amsterdam area, based on their Global Positioning System location/Internet Protocol address. As we provided the survey sequentially on two different platforms—starting with Grindr first in August 2018 during Pride Amsterdam, Gayromeo users who answered that they previously filled in the survey were excluded from the analysis.

**Sociodemographic characteristics**

Sociodemographic data we collected were: age, gender, sexuality (having sex with men, women, both) and residency (Amsterdam, elsewhere in the Netherlands, abroad). We furthermore asked whether one had been tested for STI/HIV in the past year and if they had tested at the Public Health Service of Amsterdam or elsewhere.

**Chemsex engagement characteristics**

Chemsex engagement was defined as the use of any of the following drugs before or during sex in the past 6 months: crystal methamphetamine, mephedrone, and/or GHB/GBL. Chemsex-specific characteristics that were asked included the frequency of chemsex per substance (once per month or less, 2–4 per month, 2–3 per week, ≥4 per week), frequency of condomless insertive and/or receptive anal sex during chemsex, last time having sex without any of the chemsex-associated drugs (sober sex), intravenous drug use and if so, whether needles were shared.

**NCS characteristics**

NCS was defined at the beginning of the survey as ‘sexual experience(s) where someone went beyond your limits or where you had an unpleasant experience’; this was explained with four examples: being filmed/photographed without permission, being touched against my will, had sex against my will, passed out and did not know what happened.

We asked participants whether they have had an NCS experience in the past 5 years. Then we instructed participants to think of the last NCS experience they had, we asked when those experiences happened and whether it was under the influence of chems.

To specify their own last NCS experience, participants were given the option of eight different types and one write-in option: (1) I have been filmed/photographed without permission, (2) I am blackmailed (eg, with images), (3) I have been given drugs (chems or other substances) against my will, (4) I have been touched against my will, (5) I have had sex against my will, (6) I had sex without a condom against my will, (7) I passed out (chems, other substances and/or alcohol) and do not remember what happened, (8) I have exceeded the limit of my sex partner.

Lastly, we asked for the current amount of emotional suffering due to one’s last NCS experience using a 5-point Likert scale in order to allow the participant to express how much they still emotionally suffer. Given the sensitive nature of the subject, we offered participants two different services where they could seek help regarding sexual assault.

**Statistical analysis**

Using the $\chi^2$ test for independence and Fisher’s exact test, we compared demographics and NCS experiences among participants who engaged in chemsex with those who did not. Using the $\chi^2$ test for independence and the Fisher’s exact test, we compared demographics and chemsex behaviour between men having experienced NCS with those who did not. To investigate associations of chemsex engagement with NCS, a multivariable backward logistic regression analysis was done including all variables that were associated with NCS at $p \leq 0.10$ in the univariable analysis. Chemsex engagement was forced into the model as it was the variable of interest. Additionally, the multivariable model was repeated three times to test whether the three different types of drugs were independent variables for NCS. $P < 0.05$ was considered statistically significant. Data were collected with LimeSurvey and data analyses were performed using IBM SPSS Statistics V.21.0.

**RESULTS**

Between August 2018 and August 2019, a total of 1107 (Grindr $n=828$ and Gayromeo $n=279$) participants started the survey. Due to missing data on chemsex and/or NCS experience,
previously filled in surveys, the exclusion of women and one transgender person, n=216 participants were excluded and n=891 were included in the analyses (figure 1). The median age of participants was 39 years (IQR: 30–50), 46.3% (412 of 891) had their residency in Amsterdam and 93.2% (830 of 891) reported sex with men exclusively (table 1).

Table 1  Demographics and non-consensual sexual* experiences of 273 MSM who practised and 620 MSM who did not practise chemsex† in the past 6 months, Amsterdam area, the Netherlands, between August 2018 and August 2019

| Variables | Chemsex† yes, n=273 (30.6%), n (%) | Chemsex† no, n=618 (69.4%), n (%) | P value | Total n=891 (%), n (%) |
|-----------|-----------------------------------|-----------------------------------|---------|-----------------------|
| Median age in years (IQR) | 40 (31–50) | 39 (29–49) | 0.071 | 39 (30–50) |
| Age categories in years | | | | |
| ≤24 | 22 (8.1) | 76 (12.3) | 0.054 | 98 (11.0) |
| 25–34 | 72 (26.4) | 174 (28.2) | | 246 (27.6) |
| 35–44 | 66 (24.2) | 138 (22.4) | | 204 (22.9) |
| 45–54 | 75 (27.5) | 155 (25.0) | | 230 (25.8) |
| 55–64 | 36 (13.2) | 57 (9.2) | | 93 (10.4) |
| ≥65 | 2 (0.7) | 18 (2.9) | | 20 (2.2) |
| Residence (missing n=1) | | | 0.004 | |
| Amsterdam | 106 (38.8) | 306 (49.6) | 412 (46.3) |
| Elsewhere in the Netherlands | 164 (60.1) | 298 (48.3) | 462 (51.9) |
| Abroad | 3 (1.1) | 13 (2.1) | 16 (1.8) |
| Sex in <6 months with | | | 0.076 | |
| Men | 253 (92.7) | 577 (93.4) | 830 (93.2) |
| Both men and women | 20 (7.3) | 41 (6.6) | 61 (6.8) |
| STI/HIV test in the last year | | | <0.001 | |
| No | 21 (7.7) | 170 (27.5) | 191 (21.4) |
| Yes, at the Public Health Service of Amsterdam | 71 (26.0) | 183 (29.6) | 254 (28.5) |
| Yes, elsewhere | 181 (66.3) | 265 (42.9) | 446 (50.1) |
| Condomless anal chemsex | | | | n.a. |
| Frequency | | | | |
| Always without | 72 (35.6) | n.a. | | |
| Most of the time without | 53 (26.2) | n.a. | | |
| Sometimes with | 38 (18.8) | n.a. | | |
| Most of the time with | 39 (19.3) | n.a. | | |
| Always with | 0 | n.a. | | |
| Non-consensual sexual experience* in the past 5 years | | | | |
| Yes | 58/273 (21.2) | 103/618 (16.7) | 0.109 | 161/891 (18.1) |
| Timeframe (missing n=3) | | | 0.002 | |
| Past month | 9/56 (16.1) | 4/102 (3.9) | 13/158 (8.2) |
| 1–3 months ago | 12/56 (21.4) | 7/102 (6.9) | 19/158 (12.0) |
| 3–6 months ago | 7/56 (12.5) | 12/102 (11.8) | 19/158 (12.0) |
| 6–12 months ago | 6/56 (10.7) | 14/102 (13.7) | 20/158 (12.7) |
| >1 year ago | 22/56 (39.3) | 65/102 (63.7) | 87/158 (55.1) |
| Types of experience (multiple answers possible) | | | | |
| Filmed/photographed without consent | 15 (25.9) | 14 (25.9) | 0.058 | 29 (18.0) |
| Blackmailed (eg, with images) | 4 (6.9) | 4 (6.9) | 0.460 | 8 (5.0) |
| Used drugs against my will | 10 (17.2) | 9 (17.2) | 0.130 | 19 (11.8) |
| Touched against my will | 13 (22.4) | 41 (39.8) | 0.036 | 54 (33.5) |
| Had sexual contact against my will | 17 (29.3) | 37 (35.9) | 0.487 | 54 (33.5) |
| Had sex without a condom against my will | 12 (20.7) | 26 (25.2) | 0.566 | 38 (23.6) |
| I passed out and don’t remember (under influence of chems, other substances and/or alcohol) | 24 (41.4) | 9 (8.7) | <0.001 | 33 (20.5) |
| I crossed the limits of my sex partner | 4 (6.9) | 8 (7.8) | 0.999 | 12 (7.5) |
| Other | 1 (1.7) | 5 (4.9) | 0.420 | 6 (3.7) |
| Current level of suffering (missing n=4) | | | 0.539 | |
| - no suffering | 25 (44.6) | 36 (35.6) | 61 (38.9) |
| - low suffering | 18 (32.1) | 42 (41.6) | 60 (38.2) |
| → medium suffering | 8 (14.3) | 14 (13.9) | 22 (14.0) |
| + a bit suffering | 4 (7.1) | 4 (4.0) | 8 (5.1) |
| + suffering a lot | 1 (1.8) | 5 (5.0) | 6 (3.8) |

*Non-consensual sexual experience was defined as 'where someone went beyond one’s limits or where one had an unpleasant experience'.
†The use of any combination of drugs, including crystal methamphetamine, mephedrone, and/or gamma-hydroxybutyrate/gamma-butyrolactone before or during sex in past 6 months.
MSM, men who have sex with men; n.a., not applicable; NCS, non-consensual sex.
**Health services research**

### Table 2  Chemsex* behaviour and drug used, among 161 MSM who reported non-consensual sexual experience† and 730 MSM who did not, in Amsterdam, the Netherlands between August 2018 and August 2019

| Variables | Non-consensual sexual experience, yes n=161 (18.1%), n (%) | Non-consensual sexual experience, no n=730 (81.9%), n (%) | P value | Total n=891 (%), n (%) |
|-----------|-----------------------------------------------------------|----------------------------------------------------------|---------|-----------------------|
| Median age (IQR), years | 33 (25–46) | 40 (30–50) | <0.001 | 39 (30–50) |
| Age categories, years (missing n=2) | | | | |
| ≤24 | 36 (22.4) | 62 (8.5) | 98 (11.0) |
| 25–34 | 49 (30.4) | 197 (27.0) | 246 (27.6) |
| 35–44 | 29 (18.0) | 175 (24.0) | 204 (22.9) |
| 45–54 | 34 (21.1) | 196 (26.8) | 230 (25.8) |
| 55–64 | 11 (6.8) | 82 (11.2) | 93 (10.4) |
| ≥65 | 2 (1.2) | 18 (2.5) | 20 (2.2) |
| Sex in <6 months with | | | | 0.003 |
| Men | 141 (87.6) | 689 (94.4) | 830 (93.2) |
| Both men and women | 20 (12.4) | 41 (5.6) | 61 (6.8) |
| Residency (missing n=1) | | | | 0.729 |
| Amsterdam | 78 (48.4) | 334 (45.8) | 412 (46.3) |
| Outside of Amsterdam | 81 (50.3) | 381 (52.3) | 462 (51.9) |
| Abroad | 2 (1.2) | 14 (1.9) | 16 (1.8) |
| STI/HIV test in the last year | | | | 0.561 |
| No | 30 (18.6) | 161 (22.1) | 191 (21.4) |
| Yes, at the Public Health Service of Amsterdam | 50 (31.1) | 204 (27.9) | 254 (28.5) |
| Yes, somewhere else | 81 (50.3) | 365 (50.0) | 446 (50.1) |
| Chemsex* <6 months | 58 (36.0) | 215 (29.5) | 273 (30.6) |
| GHB/GBL (G) use during sex <6 months | 53 (32.9) | 200 (27.4) | 253 (28.4) |
| Frequency | | | | 0.053 |
| Once per month or less | 22/53 (41.5) | 120/200 (60.0) | 142/253 (56.1) |
| 2–4 per month | 23/53 (43.4) | 67/200 (33.5) | 90/253 (35.6) |
| 2–3 a week | 4/53 (7.5) | 7/200 (3.5) | 11/253 (4.3) |
| ≥4 a week | 4/53 (7.5) | 6/200 (3.0) | 10/253 (4.0) |
| Crystal methamphetamine (C) use during sex <6 months | 25 (15.5) | 62 (8.5) | 87 (9.8) |
| Frequency | | | | 0.434 |
| Once per month or less | 14/25 (56.0) | 46/62 (74.2) | 60/87 (69.0) |
| 2–4 per month | 8/25 (32.0) | 12/62 (19.4) | 20/87 (23.0) |
| 2–3 a week | 5/25 (20.0) | 4/62 (6.5) | 9/87 (10.3) |
| ≥4 a week | 5/25 (20.0) | 3/62 (4.8) | 8/87 (9.1) |
| Mephedrone (M) use during sex <6 months | 20 (12.4) | 47 (6.4) | 67 (7.5) |
| Frequency | | | | 0.059 |
| Once per month or less | 11/20 (55.0) | 39/47 (83.0) | 50/67 (74.6) |
| 2–4 per month | 5/20 (25.0) | 4/47 (8.5) | 9/67 (13.4) |
| 2–3 a week | 2/20 (10.0) | 1/47 (2.1) | 3/67 (4.5) |
| ≥4 a week | 2/20 (10.0) | 3/47 (6.4) | 5/67 (7.5) |
| Type of chemsex drugs used during sex <6 months | | | | 0.078 |
| G only | 24/58 (41.4) | 129/215 (60.0) | 153/273 (56.0) |
| G and C | 9/58 (15.5) | 30/215 (14.0) | 39/273 (14.3) |
| G and M | 9/58 (15.5) | 20/215 (9.3) | 29/273 (10.6) |
| C and G and M | 11/58 (19.0) | 21/215 (9.8) | 32/273 (11.7) |
| C only | 5/58 (8.6) | 9/215 (4.2) | 14/273 (5.1) |
| M only | 0/58 (0) | 4/215 (1.9) | 4/273 (1.5) |
| C and M | 0/58 (0) | 2/215 (0.9) | 2/273 (0.7) |
| Injecting drugs <6 months | 10 (6.2) | 15 (2.1) | 25 (2.8) |
| Shared needles | 3/10 (30.0) | 1/15 (6.7) | 4/25 (16.0) |
| Sober sex last time§ | | | | 0.045 |
| In the past month | 36/58 (62.1) | 166/215 (77.2) | 202/273 (74.0) |
| Longer than 3 months ago | 5/58 (8.6) | 20/215 (9.3) | 25/273 (9.2) |
| Longer than 6 months ago | 5/58 (8.6) | 11/215 (5.1) | 16/273 (5.9) |
| Longer than 1 year ago | 8/58 (13.8) | 14/215 (6.5) | 22/273 (8.1) |
| I do not remember | 4/58 (6.9) | 4/215 (1.9) | 8/273 (2.9) |

*The use of any combination of drugs, including crystal methamphetamine, mephedrone, and/or GHB/GBL before or during sex in past 6 months.
†Non-consensual sexual experience was defined as ‘where someone went beyond your limits or where you had an unpleasant experience’ (eg, filmed/photographed without consent, had sexual contact against their will, etc).
‡It is not known whether drugs were consumed at the same time or sequential.
§Last time having sex without any of the chemsex-associated drugs.
GHB/GBL, gamma-hydroxybutyrate/gamma-butyrolactone; MSM, men who have sex with men.
| Determinant                              | Univariable, OR (95% CI) | P value | Multivariable, aOR (95% CI) | P value | Multivariable, aOR (95% CI) | P value | Multivariable, aOR (95% CI) | P value | Multivariable, aOR (95% CI) | P value | Multivariable, aOR (95% CI) | P value |
|-----------------------------------------|--------------------------|---------|-----------------------------|---------|-----------------------------|---------|-----------------------------|---------|-----------------------------|---------|-----------------------------|---------|
| **Age (IQR), years**                    | 0.96 (0.90 to 0.98)      | <0.001  | 0.96 (0.93 to 0.98)         | <0.001  | 0.97 (0.95 to 0.98)         | <0.001  | 0.96 (0.95 to 0.98)         | <0.001  | 0.96 (0.95 to 0.98)         | <0.001  | 0.96 (0.95 to 0.98)         | <0.001  |
| **Condomless anal chemsex**             |                          |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| No                                      | 1                        |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Yes                                     | 1.33 (0.90 to 1.96)      |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| **Sex in <6 months with Men and Women** |                          |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Men                                     | 2.38 (1.36 to 4.19)      | 0.003   | 2.21 (1.24 to 3.92)         | 0.007   | 2.10 (1.18 to 3.75)         | 0.012   | 2.20 (1.24 to 3.91)         | 0.007   | 2.22 (1.23 to 3.96)         | 0.007   |                             |         |
| Men and women                           | 2.38 (1.36 to 4.19)      | 0.003   | 2.21 (1.24 to 3.92)         | 0.007   | 2.10 (1.18 to 3.75)         | 0.012   | 2.20 (1.24 to 3.91)         | 0.007   | 2.22 (1.23 to 3.96)         | 0.007   |                             |         |
| **Chemsex <6 months**                   |                          |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Not using chems during sex              | 1                        | 0.102   | 0.80 (0.60 to 1.06)         | 0.044   |                             |         |                             |         |                             |         |                             |         |
| Using chems during sex                  | 1.46 (1.01 to 2.11)      |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| **Mephedrone (M) use <6 months**        |                          |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Not using M during sex                  | 1                        | 0.010   |                             |         |                             |         |                             |         |                             |         |                             |         |
| Using M during sex                      | 2.06 (1.19 to 3.59)      |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| **GHB/GBL (G) use <6 months**           |                          |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Not using G during sex                  | 1                        | 0.160   |                             |         |                             |         |                             |         |                             |         |                             |         |
| Using G during sex                      | 1.93 (1.10 to 3.40)      |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| **Crystal methamphetamine use (C) <6 months** |                |         |                             |         |                             |         |                             |         |                             |         |                             |         |
| Not using C during sex                  | 1                        | 0.007   |                             |         |                             |         |                             |         |                             |         |                             |         |
| Using C during sex                      | 1.98 (1.20 to 3.26)      |         |                             |         |                             |         |                             |         |                             |         |                             |         |

*Non-consensual sexual experience was defined as ‘where someone went beyond your limits or where you had an unpleasant experience’ (e.g. filmed/photographed without consent, had sexual contact against their will).†The use of any combination of drugs, including crystal methamphetamine, mephedrone, and/or GHB/GBL before or during sex. aOR, adjusted OR; GHB/GBL, gamma-hydroxybutyrate/gamma-butyrolactone; MSM, men who have sex with men.*
Of all participants, 30.6% (273 of 891) engaged in chemsex in the past 6 months.

**NCS experiences**

Of all participants, 161 of 891 (18.1%) reported at least one NCS experience in the past 5 years (table 1). Overall, the group of participants engaging in chemsex and the group of participants who did not engage in chemsex did not differ in prevalence of NCS in the past 5 years (58 of 237, 21.2% vs 103 of 618, 16.7%; p=0.109). However, among participants who reported NCS, two specified types of NCS differed significantly between chemsex and non-chemsex engagers: (1) MSM who engaged in chemsex reported ‘being touched against one’s will’ less often (13 of 58; 22.4% vs 41 of 103; 39.8%; p=0.036). (2) MSM who engaged in chemsex reported ‘having passed out and not remembering what happened during drug use’ (all possible drugs and/or alcohol) more often (24 of 58; 41.4% vs 9 of 103; 8.7%; p=0.001).

Participants who engaged in chemsex and had NCS reported more recent NCS experiences than participants who did not engage in chemsex and had NCS (p=0.002); meaning most participants (65 of 102; 63.7%) in the non-chemsex group reported that their most recent NCS experience was longer than 1 year ago (chemsex group: 22 of 56; 39.3%).

Most participants (77.1%) rated the level of current suffering due to one’s last NCS on a 5-point Likert scale with no suffering at all (61 of 161; 38.9%) or low suffering (60 of 161; 38.2%) and this was not significantly different between participants who engaged in chemsex and who did not (p=0.539). However, 1.8% (1 of 58) of participants engaged in chemsex and 5.0% (5 of 103) of participants did not rate their suffering with the highest possible option (suffering a lot). In online supplemental tables 1 and 2, we display the amount of suffering in relation to the different types of NCS and timeframe.

**NCS experiences and chemsex characteristics**

Participants who experienced NCS were younger (median 33 vs 40; p<0.001), more often crystal methamphetamine users (15.5% vs 8.5%; p=0.009) and reported more often intravenous drug use (6.2% vs 2.1%; p=0.008) compared with participants who did not experience NCS (table 2).

Participants who engaged in chemsex and reported NCS differed significantly from those who also engaged in chemsex but did not report NCS as far as having had sober sex in the last month and not remembering the last time they had sober sex (overall p=0.045).

**Associations with NCS experiences**

In the univariable analysis, chemsex engagement in the past 6 months was not associated with NCS in the past 5 years (OR 1.35; 95% CI 0.94 to 1.93) (table 3).

Whereas age (OR 0.96; 95% CI 0.90 to 0.98), having sex with both men and women, as opposed to with men only (OR 2.38; 95% CI 1.36 to 4.19), mephedrone use (OR 2.06; 95% CI 1.19 to 3.59) and crystal methamphetamine use in the past 6 months (OR 1.98; 95% CI 1.20 to 3.26) were significant determinants of NCS.

In the multivariable regression analyses, chemsex engagement in the past 6 months was associated with NCS (adjusted OR (aOR) 1.46; 95% CI 1.01 to 2.11), as well as younger age (aOR 0.96; 95% CI 0.95 to 0.98) and having sex with both men and women as opposed to men only (aOR 2.21; 95% CI 1.24 to 3.92). In the multivariable model for the three different types of drugs as independent variable for NCS, significant associations were found for mephedrone (aOR 1.93; 95% CI 1.10 to 3.40) and crystal methamphetamine use (aOR 2.18; 95% CI 1.25 to 3.96).

**DISCUSSION**

In this study, we found that a considerable proportion of MSM recently engaged in chemsex and had an NCS experience in the past 5 years. Moreover, in a multivariate logistic regression analysis, we established that chemsex engagement is associated with NCS. The advertisement strategy via online gay dating platforms gave insight in the Dutch chemsex subculture and the associations with NCS.

In our study, the overall prevalence of NCS was 18.1% in the past 5 years. A bit less than the half (44.9%) of all experiences was within the past year. In an earlier report on sexual violence (defined as ‘forced into sex’) among men in the Netherlands (sexual preference was not specified), the lifetime prevalence was 6%. When including all sexual transgressive behaviour, which also includes kissing and sexual contiguity, they reported a 19% lifetime prevalence. Findings published by Haas showed a 7.7% lifetime prevalence of sexual violence among men. This percentage dropped to 1.2% when only focusing on the previous year. In our study, we find much higher percentages; in the chemsex group 12.5% of all participants reported NCS in the past year only (vs 6.0% among non-chemsex engagers; p=0.002). The difference between both groups suggests that MSM engaging in chemsex experience NCS more frequently and therefore more recently. However, the definition or concept used to describe NCS in the literature often varies and can lead to differences in findings. For example, Ward et al found a 42.9% prevalence among chemsex users after changing the terminology from ‘forced into sex’ to ‘non-consensual sex’ compared with 16.7% before. We therefore purposely chose to use the term ‘non-consensual sex’ to include as many forms of sexually transgressive behaviour as possible. To prevent a misinterpretation, yet also gather more in-depth information on participants’ own specific experiences, we offered some examples of NCS at the start, and enquired their own specific experiences at the end of the survey.

Among men who practise chemsex, sexual consent can be experienced as complicated and vague. In a qualitative study of Bourne et al among MSM engaging in chemsex, 10% of the participants reported to have overdosed on GHB with loss of consciousness and therefore could not have given consent to the sex which occurred but still did not refer to it as sexual assault or rape. In our study also, 8.8% of all chemsex engagers reported loss of consciousness due to chems, other substances and/or alcohol. Besides the feelings of guilt and shame that could go along with NCS, the cognitive dissonance theory could explain that men who attend chemsex parties might accept this ambiguity, change their attitudes towards consent (to avoid dissonance) and set a norm in which participation in such a party equals consent. This also might explain why most participants in our study who had an NCS experience reported little to no emotional distress afterwards. However, 1.8% (1 of 58) of MSM engaging in chemsex and 5.0% (5 of 103) of the MSM not engaging in chemsex rated their suffering with the highest option possible. This is in line with our finding that in the non-chemsex group, ‘being touched against one’s will’ was reported more often compared with the chemsex group. However, we do not know whether men engaging in chemsex talked beforehand about the possibility of passing out
during a chemsex session and which rules would apply at this point regarding consent.

In our study, we found that men having sex with both men and women compared with men having sex with men only have higher odds of an NCS experience in the past 5 years. Earlier studies also found that bisexual individuals are more vulnerable to mental health issues, show poorer social and psychological well-being, and report a poorer overall health compared with gay men or other sexual minority. However, the terminology bisexuality often is used as identity measure and in our study we only asked the gender of the sex partners and therefore cannot clearly interpret this.

A strength of our study was that the survey was anonymous, therefore participants might have felt particularly open to disclose both chemsex engagement and NCS. Healthcare workers need to be aware that criminalisation, shame and stigma form barriers to disclose chemsex and NCS in institutional settings. It is necessary to develop strategies in which frontline workers need to be aware that criminalisation, shame and stigma form barriers to disclose chemsex and NCS in institutional settings. It is necessary to develop strategies in which stimulant drug use. Referral to other healthcare facilities specialised in chemsex or NCS remains important.

A substantial proportion of men who have sex with men (MSM) (regardless of chemsex engagement) reported non-consensual sex (NCS) in the past 5 years. In multivariate logistic regression analysis, chemsex engagement is associated with an NCS experience. Among participants who reported NCS, suffering related to NCS did not differ between chemsex engagers and non-engagers. Sexual healthcare professionals need to address chemsex and NCS during consultations involving MSM and refer men for specialised help if deemed necessary.

Handling editor Tristan J Barber

Acknowledgements The authors would like to thank Bart-Jan Mulder, Kees de Jong, Roel Achterbergh, Illya Peters, Udi Davidovich, Sjaak van de Kolk, Carien Manuels and Laura van der Meij for the support in developing the online survey.

Contributors SD and JS contributed equally to the article. JS, SD, MvR and HJCDV designed the study protocol. SD and JS performed the statistical analyses. Results were thoroughly discussed by JS, SD, MvR and HJCDV. JS and SD drafted the paper, all authors commented on draft versions and all approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Not applicable

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs Susanne Drückler http://orcid.org/0000-0001-7449-3475 Jilke Speulman http://orcid.org/0000-0002-8984-4896

REFERENCES

1 EMCDDA. Wastewater analysis and drugs: a European multi-city study, 2019.
2 Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviours among men who have sex with men: a systematic review of the literature. Int J Drug Policy 2019;63:74–89.
3 Tomkins A, George R, Kliner M. Sexualised drug taking among men who have sex with men: a systematic review. Perspect Public Health 2019;139:23–33.
4 Stuart D.A chemsex crucible: the context and the controversy. J Fam Plann Reprod Health Care 2016;42:295–6.
5 Achterbergh RCA, de Vries HIC, Boyd A, et al. Identification and characterization of latent classes based on drug use among men who have sex with men at risk...
of sexually transmitted infections in Amsterdam, the Netherlands. *Addiction* 2020;115:121–33.

6 Quinn B, Stoové M, Papanastasiou C, et al. An exploration of self-perceived non-problematic use as a barrier to professional support for methamphetamine users. *Int J Drug Policy* 2013;24:619–23.

7 Weatherburn P, Hickson F, Reid D, et al. Motivations and values associated with combining sex and illicit drugs (“chemsex”) among gay men in South London: findings from a qualitative study. *Sex Transm Infect* 2017;93:203–6.

8 Hibblet MP, Brett CE, Porcellato LA, et al. Psychosocial and sexual characteristics associated with sexualised drug use and chemsex among men who have sex with men (MSM) in the UK. *Sex Transm Infect* 2019;95:342–50.

9 Drückler S, van Rooijen MS, de Vries HJC. Chemsex among men who have sex with men: a Sexualized drug use survey among clients of the sexually transmitted infection outpatient clinic and users of a gay dating APP in Amsterdam, the Netherlands. *Sex Transm Infect* 2018;94:494–501.

10 Rositska M, Gios L, Nöstlinger C, et al. Prevalence of drug use during sex amongst MSM in Europe: results from a multi-site bio-behavioural survey. *Int J Drug Policy* 2018;55:231–41.

11 Kenyon C, Wouters K, Plateau T, et al. Increases in non-consensual chemsex associated with HIV acquisition in MSM but not heterosexuals attending a HIV testing center in Antwerp, Belgium. *AIDS Res Ther* 2018;15:14.

12 Sewell J, Cambiano V, Miltz A, et al. Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013–2016. *Sex Transm Infect* 2018;94:494–501.

13 Radfar SR, Rawson RA. Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. *Addict Health* 2014;6:146–54.

14 Boume A, Reid D, Hickson F, et al. “Chemsex” and harm reduction need among gay men in South London. *Int J Drug Policy* 2015;26:1171–6.

15 Latimer R, Vodstrcil LA, Fairley CK, et al. Non-consensual condom removal reported by patients at a sexual health clinic in Melbourne, Australia. *PloS One* 2018;13:e0209799.

16 Ward C, McQuillan Q, Evans R. O14 Chemsex, consent and the rise in sexual assault. *Sex Transm Infect* 2017;93:A5.2–A5.

17 Ahmed A-K, Weatherburn P, Reid D, et al. Social norms related to combining drugs and sex (“chemsex”) among gay men in South London. *Int J Drug Policy* 2016;38:29–35.

18 Chow EFE, Cornelisse VJ, Read TRH, et al. Risk practices in the era of smartphone Apps for meeting partners: a cross-sectional study among men who have sex with men in Melbourne, Australia. *AIDS Patient Care STDS* 2016;30:151–4.

19 Rusow JA, Fletcher JB, Reback CJ. Sexual venue choice and sexual risk-taking among Substance-Using men who have sex with men. *AIDS Behav* 2017;21:1149–62.

20 Haas Sd. Seksueel grensoverschrijdend gedrag onder jongeren en volwassenen in Nederland. *Tijdschrift voor seksuologie* 2012;36.

21 Ratner PA, Johnson JL, Shoeller JA, et al. Non-consensual sex experienced by men who have sex with men: prevalence and association with mental health. *Patient Educ Couns* 2003;49:67–74.

22 van Rooijen MS, Schim van der Loeff MF, van Kempen L, et al. Sexually transmitted infection positivity rate and treatment uptake among female and male sexual assault victims attending the Amsterdam STI clinic between 2005 and 2016. *Sex Transm Dis* 2018;45:534–41.

23 Stuart D. Chemsex first aid, 2018.

24 Rutgers. *Seksuele gezondheid in Nederland*, 2017.

25 Harmon-Jones E, Harmon-Jones C. Cognitive dissonance theory after 50 years of development. *Zeitschrift für Sozialpsychologie* 2007;38:7–16.

26 Conron KJ, Mimiga MJ, Landers SJ. A population-based study of sexual identity, orientation identity and gender differences in adult health. *Am J Orthopsychiatry* 2010;100:1953–60.

27 la Roi C, Meyer IH, Frost DM. Differences in sexual identity dimensions between bisexual and other sexual minority individuals: implications for minority stress and mental health. *Am J Orthopsychiatry* 2019;89:40–51.

28 Thompson C. Review of 212 individuals attending a City centre genito-urinary medicine clinic following acute sexual assault. *J Clin Forensic Med* 2006;13:186–8.

29 O’Halloran C, Rice B, White E, et al. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants. *Int J Drug Policy* 2019;74:246–54.

30 Sewell J, Miltz A, Lampe FC, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. *Int J Drug Policy* 2017;43:33–43.

31 Hallkits PN, Kapadia F, Bub KL, et al. A longitudinal investigation of Syndemic conditions among young gay, bisexual, and other MSM: the p18 cohort study. *AIDS Behav* 2015;19:970–80.

32 Miltz AR, Lampe FC, Bacchus LJ, et al. Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial. *BMC Public Health* 2019;19:431.